InvestSMART

Patrys Limited (ASX: PAB) - Announcements

- Current share price for PAB : $0.033

ASX company news and announcements for Patrys Limited (PAB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Patrys Limited (PAB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Patrys Limited (PAB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Patrys Limited (PAB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$22 Investor Presentation - TechKnow Invest Roadshow 27 Jul 2026 8:28AM $0.037 $0.033 fallen by 10.81%
$22 Appendix 4C - Quarterly - 30 June 2026 22 Jul 2026 9:35AM $0.036 $0.033 fallen by 8.33%
$22 Cleansing Notice 15 Jul 2026 6:13PM $0.038 $0.033 fallen by 13.16%
$22 Notification regarding unquoted securities - PAB 15 Jul 2026 6:12PM $0.038 $0.033 fallen by 13.16%
$22 Application for quotation of securities - PAB 15 Jul 2026 6:08PM $0.038 $0.033 fallen by 13.16%
$22 Patrys Secures 50% Revenue Share in IP Commercialisation 13 Jul 2026 8:22AM $0.040 $0.033 fallen by 17.50%
$22 Becoming a substantial holder 7 Jul 2026 6:14PM $0.038 $0.033 fallen by 13.16%
$22 Change of Director's Interest Notices x4 3 Jul 2026 6:14PM $0.039 $0.033 fallen by 15.38%
$22 Notification regarding unquoted securities - PAB 3 Jul 2026 6:11PM $0.039 $0.033 fallen by 15.38%
$22 Cleansing Notice 3 Jul 2026 6:09PM $0.039 $0.033 fallen by 15.38%
$22 Application for quotation of securities - PAB 3 Jul 2026 6:06PM $0.039 $0.033 fallen by 15.38%
$22 Proposed issue of securities - PAB 9 Jun 2026 8:28AM $0.042 $0.033 fallen by 21.43%
$22 Results of Meeting 9 Jun 2026 8:26AM $0.042 $0.033 fallen by 21.43%
$22 Patrys advances RLS-2202 toward Phase 1 Clinical Trial 20 May 2026 9:31AM $0.032 $0.033 risen by 3.13%
$22 Appendix 4C - Quarterly - 31 March 2026 - Updated 15 May 2026 6:20PM $0.031 $0.033 risen by 6.45%
$22 Letter to Shareholders - General Meeting 6 May 2026 8:17AM $0.029 $0.033 risen by 13.79%
$22 Notice of General Meeting/Proxy Form 6 May 2026 8:17AM $0.029 $0.033 risen by 13.79%
$22 Appendix 4C - Quarterly - 31 March 2026 30 Apr 2026 9:13AM $0.031 $0.033 risen by 6.45%
$22 Cleansing Notice 29 Apr 2026 8:48AM $0.030 $0.033 risen by 10%
$22 Application for quotation of securities - PAB 29 Apr 2026 8:44AM $0.030 $0.033 risen by 10%
$22 Proposed issue of securities - PAB 20 Apr 2026 9:31AM $0.026 $0.033 risen by 26.92%
$22 $3.2 million Placement to Advance Clinical Trials 20 Apr 2026 9:31AM $0.026 $0.033 risen by 26.92%
$22 Trading Halt 16 Apr 2026 8:53AM $0.026 $0.033 risen by 26.92%
$22 Investor Presentation - Broker Meets Biotech 31 Mar 2026 8:21AM $0.028 $0.033 risen by 17.86%
$22 Notification of cessation of securities - PAB 18 Mar 2026 7:36PM $0.032 $0.033 risen by 3.13%

1 - 25 of 679 results

Page 1 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.